1. S. Boyle-Vavra and R. S. Daum, Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leucocidin. Lab Invest. 2007, 87, 3-9.
2. International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements. Classification of Staphylococcal Cassette Chromosome mec (SCCmec): Guidelines for Reporting Novel SCCmec Elements, Antimicrob. Agents Chemother. 2009, 53, 4961–4967
3. 今井 大助, 馬 笑雪, 柳川 宏之, 伊藤 輝代, 平松 啓一, 黒澤 尚. 本邦の MRSA の薬剤感受性とSCCmec のタイプ, Juntendo Medical Journal, 2003, 49, 343-354.
4. K. P. Klugman and S. Black, Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. PNAS, 2018, 115, 12896-12901
5. C. P. Andam, C. J. Worby, R. Gierke, L. McGee, T. Pilishvili, and W. P. Hanage, Penicillin Resistance of Nonvaccine Type Pneumococcus before and after PCV13 Introduction, United States. Emerg Infect Dis. 2017, 23, 1012–1015.
6. S. Garneau-Tsodikovaa and K. J. Labby. Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Medchemcomm. 2016, 7, 11–27.
7. T. Matsumoto, H. Hanaki, T. Kimura, M. Nemoto, M. Higashihara, H. Yokota, S. Oda, N. Akiyama, N. Miyao, M. Yoshida, T. Yukioka, K. Soma, K. Ohyashiki, Y. Suzuki, T. Arai, K. Ikegami, T. Ichiwata, Y. Otsuka, M. Kobayashi, K. Totsuka, K. Sunakawa, and ABK Dose Finding Study Group, Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother. 2013, 19, 128-37.
8. V. F. Vandenesch, T. Naimi, M. C. Enright, G. Lina, G. R. Nimmo, H. Heffernan, N. Liassine,M. Bes, T. Greenland, M. E. Reverdy, and Jerome Etiennecorresponding author. Community- acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9, 978-984.
9. C. R. Frei, M. L Miller, J. S. Lewis 2nd, K. A. Lawson, J. M. Hunter, C. U. Oramasionwu, and R. L. Talbert, Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med. 2010, 23, 714-719.
10. M. Patel, K. B. Waites, S. A. Moser, G. A. Cloud, and C. J. Hoesley, Prevalence of Inducible Clindamycin Resistance among Community- and Hospital-Associated Staphylococcus aureus Isolates. J Clin Microbiol. 2006, 44, 2481–2484.
11. S. L. Green, J. C. Maddox, and E. D. Huttenbach, Linezolid and reversible myelosuppression. JAMA, 2001, 14, 285, 1291.
12. H. Goto, K. Shimada, H. Ikemoto, T. Oguri, and Study Group on Antimicrobial Susceptibility of Pathogens Isolated from Respiratory Infections, Antimicrobial susceptibility of pathogens isolated from more than 10000 patients with infectious respiratory diseases: a 25-year longitudinal study. J. Infect. Chemother. 2009, 15, 347–360.
13. G. V. Doern, S. S. Richter, A. Miller, N. Miller, C. Rice, K. Heilmann, and S. Beekmann, Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 2005, 41, 139– 148.
14. M. Kurazono, T. Ida, K. Yamada, Y. Hirai, T. Maruyama, E. Shitara, and M. Yonezawa, In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 2004, 48, 2831–2837.
15. J. Nagura, K. Kijima, M. Kurazono, S. Takahata, T. Sugano, Y. Tanaka, Y. Hirai, K. Yamada, Y. Takayama, E. Shitara, and M. Yonezawa, Therapeutic Effect of ME1036 on Endocarditis Experimentally Induced by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2005, 49, 3526–3528.
16. J. Nagura, T. Sugano, A. Yamamoto, Y. Takase, S. Sakakibara, H. Takata, K. Matsumoto, E. Shitara and M. Yonezawa, CP5609, a Novel Parenteral Carbapenem: Efficacy on Experimental Endocarditis due to Methicillin-Resistant Staphylococcus aureus. 2002, 42nd ICAAC, F321.
17. M. Yonezawa, J. Nagura, Y. Takase, T. Sugano, Y. Takayama T. Takata, A. Shimizu, S. Sakakibara, H. Takata, K. Matsumoto, K. Tohyama and E. Shitara, CP5609, a Novel Parenteral Carbapenem: In Vivo Activities against Methicillin-Resistant S. aureus, Penicillin-Resistant S. pneumoniae and β-Lactamase Negative Ampicillin-Resistant H. influenza. 2002, 42nd ICAAC, F322
18. J. Nagura, Y. Takayama, K. Kijima, M. Yamamoto, T. Yoshida and M. Yonezawa, ME1036, a Novel Parenteral Carbapenem: Efficacy on Mouse Subcutaneous Abscesses Due to Methicillin- Resistant Staphylococcus aureus. 2005, 45th ICAAC F1450
19. E. Matsuhisa, K. Hasunuma, H. Suzuki, M. Ogawa, N. Senju, E. Shitara, and M. Yonezawa, CP5609, a Novel Parenteral Carbapenem: Pre-Clinical Toxicological Profile. 2002, 42nd ICAAC, F323
20. K Kosowska-Shick, P. L. McGhee, and P. C. Appelbaum, Affinity of ceftaroline and other beta- lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2010, 54, 1670–1677.
21. M. Yamada, T. Watanabe, N. Baba, Y. Takeuchi, F. Ohsawa, and S. Gomi, Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2008, 52, 2053–2060.
22. C. Contreras-Martel, C. Dahout-Gonzalez, A. D. S. Martins, M. Kotnik, and A. Dessen, PBP active site flexibility as the key mechanism for beta-lactam resistance in pneumococci. J. Mol. Biol. 2009, 387, 899–909.
23. F. Cafini, R. del Campo, L. Alou, D. Sevillano, M. I. Morosini, F. Baquero, J. Prieto, and Spanish Pneumococcal Network (G03/103), Alterations of the penicillin-binding proteins and murM alleles of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin in Spain. J. Antimicrob. Chemother. 2006, 57, 224–229.
24. A. Dalhoff, T. Nasu, and K. Okamoto, Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria. Chemotherapy 2003, 49, 172–183.
25. P. L. Ho, S. S. Chiu, I. Ang, and Y. L. Lau, Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995–2009. Vaccine 2011, 29, 3270–3275.
26. M. H. Rozenbaum, C. Boersma, M. J. Postma, and E. Hak. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev. Vaccines 2011, 10, 187–199.
27. K. H. Yao, L. B. Wang, G. M. Zhao, Y. J. Zheng, L. Deng, J. F. Huang, J. X. Wang, R. Z. Zhao,Q. L. Deng, Y. H. Hu, S. J. Yu, Y. H. Yang, and M. Young, Pneumococcal serotype distribution and antimicrobial resistance in Chinese children hospitalized for pneumonia. Vaccine 2011, 29, 2296–2301.
28. S. Tokajian, New epidemiology of Staphylococcus aureus infections in the Middle East. Clin Microbiol Infect. 2014, 20, 624–628.
29. C. J. Chen and Y. C. Huang, New epidemiology of Staphylococcus aureus infection in Asia. Clin Microbiol Infect. 2014, 20, 605–623.
30. Y. Sharma, S. Jain, H. Singh, and V. Govil, Staphylococcus aureus: Screening for nasal carriers in a community setting with special reference to MRSA. Science. 2014, 479048.
31. G. W. Coombs, S. Monecke, J. C. Pearson, H. L. Tan, Y. K. Chew, L. Wilson, R. Ehricht, F. G. O'Brien, and K. J. Christiansen, Evolution and diversity of community-associated methicillinresistant Staphylococcus aureus in a geographical region. BMC Microbiol. 2011, 11, 215.
32. P. Cocchi, G. Taccetti, C. Montagnani, L. Galli, C. Braggion, and M. de Martino, Evidence of transmission of a Panton-Valentine leukocidin-positive community-acquired methicillin- resistant Staphylococcus aureus clone: a family affair. Clin Microbiol Infect. 2013, 19, 1158– 1162.
33. V. Shetty, K. Trumbull, A. Hegde, V. Shenoy, R. Prabhu, K. Sumathi, E. Palavecino, and A. K. Shetty, Prevalence of community-acquired methicillin-resistant Staphylococcus aureus nasal colonization among children. J Clin Diagn Res. 2014, 8, DC12–5.
34. W. T. Lo, W. J. Lin, M. H. Tseng, J. J. Lu, S. Y. Lee, M. L. Chu, and C. C, Wang, Nasal carriage of a single clone of community-acquired methicillin-resistant Staphylococcus aureus among kindergarten attendees in Northern Taiwan. BMC Infect Dis. 2007, 7, 51.
35. Z. Ali, N. Mumtaz, S. A. Naz, N. Jabeen, and M. Shafique, Multi-drug resistant Pseudomonas aeruginosa: a threat of nosocomial infections in tertiary care hospitals. J Pak Med Assoc. 2015, 65, 12–16.
36. A. C. S. Rodrigues, M. R. Chang, G. D. Nóbrega, M. S. Rodrigues, N. C. P. Carvalho, B. G. Gomes, D. L. Almeida, K. R. Carvalho, and M. D. Asensi, Metallo-β-lactamase and genetic diversity of Pseudomonas aeruginosa in intensive care units in Campo Grande, MS, Brazil. Braz J Infect Dis. 2011, 15, 195–199.
37. J.A. Karlowsky, D. J. Hoban, M. A. Hackel, S. H. Lob, and D. F. Sahm, Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. J Med Microbiol. 2017, 66, 61–69.
38. J. R. Mediavilla, A. Patrawalla, L. Chen, K. D. Chavda, B. Mathema, C. Vinnard, L. L Dever, and B. N. Kreiswirth, Colistin- and carbapenem-resistant Escherichia coli harboring mcr-1 and blaNDM-5, causing a complicated urinary tract infection in a patient from the United States. MBio. 2016, 30, 7.
39. Y. Hiraiwa, N. Minowa, T. Usui, Y. Akiyama, K. Maebashi, and D. Ikeda, Effect of varying the 4”-position of arbekacin derivatives on antibacterial activity against MRSA and Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2007, 17, 6369–6372.
40. Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement. Clinical and Laboratory Standards Institute. 2012, M100-S22.
41. S. Kondo, K. Iinuma, and H. Yamamoto, Syntheses of 1-N-(S)-4-amino-2-hydroxybutyryl)- kanamycin B and -3′, 4′-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot. 1973, 26, 412–415.
42. Y. Hiraiwa, T. Usui, Y. Akiyama, K. Maebashi, and N. Minowa. Synthesis and antibacterial activity of 5-deoxy-5-episubstituted arbekacin derivatives. Bioorg Med Chem Lett. 2007, 17, 3540–3543.
43. S. Magnet and J. S. Blanchard, Molecular insights into aminoglycoside action and resistance. Chem Rev. 2005, 105, 477–498.
44. H. Goto and M. Iwasaki, Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibacterial agents (2010). Jpn J Antibiot. 2015, 68, 85–104.
45. T. Matsumoto, Arbekacin: another novel agent for treating infections due to methicillin- resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens. Clin Pharmacol. 2014, 6, 139–148.
46. S. Y. Holbrook and S. Garneau-Tsodikova, Expanding aminoglycoside resistance enzyme regiospecificity by mutation and truncation. Biochemistry. 2016, 55, 5726–5737.
47. M. Tabata, M. Shimizu, M. Araake, and H. Ogawa, Relationship between arbekacin- susceptibility and aminoglycoside-resistant gene of methicillin-resistant Staphylococcus aureus (MRSA). Jpn J Antibiot. 2003, 56, 36–43.
48. P. Keith, Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005, 49, 479–487.
49. R. T. Cass, C. D. Brooks, N. A. Havrilla, K. J. Tack, M. T. Borin, D. Young, and J. B. Bruss, Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother. 2011, 55, 5874–5880.
50. J. W. Agostino, J. K. Ferguson, K. Eastwood, and M. D. Kirk, The increasing importance of community-acquired methicillin-resistant Staphylococcus aureus infections. Med J Aust. 2017, 207, 388-93.
51. G. W. Coombs, D. A. Daly, J. C. Pearson, G. R. Nimmo, P. J. Collignon, M. L. McLaws, J. O. Robinson, J. D. Turnidge, and Australian Group on Antimicrobial Resistance, Community- onset Staphylococcus aureus Surveillance Programme annual report, 2012. Commun Dis Intell Q Rep. 2014, 38, E59-69.
52. A. E. Peterson, M. F. Davis, K. G. Julian, G. Awantang, W. H. Greene, L. B. Price, A. Waters,A. Doppalapudi, L. J. Krain, K. Nelson, E. K. Silbergeld, and C. J. Whitener, Molecular and Phenotypic Characteristics of Healthcare- and Community-Associated Methicillin-Resistant Staphylococcus aureus at a Rural Hospital. PLoS One. 2012, 7, e38354.
53. S. Flanagan, E. E McKee, D. Das, P. M. Tulkens, H. Hosako, J. Fiedler-Kelly, J. Passarell, A. Radovsky, and P. Prokocimer, Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015, 59, 178-185.
54. S. Iguchi, T. Mizutani, K. Hiramatsu, and K. Kikuchi, Rapid Acquisition of Linezolid Resistance in Methicillin-Resistant Staphylococcus aureus: Role of Hypermutation and Homologous Recombination. PLOS ONE. 2016, 11, e0155512
55. Y. Wakiyama, K. Kumura, E. Umemura, S. Masaki, K. Ueda, Y. Sato, Y. Hirai, Y. Hayashi, and K. Ajito, Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions. J Antibiot. 2018, 71, 298-317
56. O. K A. Hassan, M. Karnib, R. El-Khoury, G. Nemer, M. Ahdab-Barmada, and P. B. Khalil, Linezolid Toxicity and Mitochondrial Susceptibility: A Novel Neurological Complication in a Lebanese Patient. Frontiers in Pharmacology, 2016, 7, 325-329
57. S. Douthwaite. Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA. Nucleic Acids Res 1992, 20, 4717–4720.
58. M. Z. David and R. S. Daum, Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010, 23, 616-687
59. L. Braun, D. Craft, R. Williams, F. Tuamokumo, and M. Ottolini, Increasing clindamycin resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States military treatment facilities. Pediatr Infect Dis J. 2005, 24, 622-626.
60. Y. Wakiyama, K. Kumura, E. Umemura, S. Masaki, K. Ueda, T. Watanabe, M. Yamamoto, Y. Hirai and K. Ajito, Synthesis and structure–activity relationships of novel lincomycin derivatives. Part 2. Synthesis of 7(S)-7-deoxy-7-(4-morpholino carbonylphenylthio) lincomycin and its 3-dimensional analysis with rRNA. J Antibiot. 2016, 69, 428-39.
61. C. Davidovich, A. Bashan, and A. Yonath. Structural basis for cross-resistance to ribosomal PTC antibiotics. PNAS. 2008, 105, 20665–20670.
62. H. Moisan, M. Pruneau, and F. Malouin. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 2010, 65, 713-716
63. Y. Asahi, Y. Takeuchi and K. Ubukata. Diversity of Substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in Cephalosporin-Resistant Streptococcus pneumoniae isolates. Antimicrobial Agents and Chemotherapy. 1999, 43, 1252– 1255
64. F. M.E. Wagenlehner, D. J. Cloutier, A. S. Komirenko, D. S. Cebrik, K. M. Krause, T. R. Keepers, L. E. Connolly, L. G. Miller, I. Friedland, and J. P. Dwyer for the EPIC Study Group, Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019, 380, 729-740
65. R. Kobayashi, M. Konomi, K. Hasegawa, M. Morozumi, K. Sunakawa, and K. Ubukata, In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2005, 49, 889–894.
66. K. Ubukata, N. Chiba, K. Hasegawa, R. Kobayashi, S. Iwata, and K. Sunakawa, Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 2004, 48, 1488–1494.
67. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A7 (Clinical and Laboratory Standards Institute: Wayne, PA, 2006).
68. P. Garcia, J. L. Garcia, E. Garcia, and R. Lopez, Nucleotide sequence and expression of the pneumococcal autolysin gene from its own promotor in Escherichia coli. Gene 1986, 43, 265– 272.
69. Y. Utsui and T. Yokota, Role of an altered penicillin-binding protein in methicillinand cephem- resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 1985, 28, 397–403.
70. R. G. Spratt, Distinct penicillin binding proteins involved in the division, elongation and shape of Escherichia coli K12. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 2999-3003.
71. T. Ida, R. Okamoto, C. Shimauchi, T. Okubo, A. Kuga, and M. Inoue, Identification of Aminoglycoside-Modifying Enzymes by SusceptibilityTesting: Epidemiology of Methicillin- Resistant Staphylococcus aureus in Japan. Journal of Clinical Microbiology, 2001, 39, 3115- 3121.
72. N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, and T. Nishino, Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000, 44, 2242–2246.
73. Y. Takahashi, E. Umemura, Y. Kobayashi, S. Murakami, T. Nawa, A. Morinaka, T. Miyake, and M. Shibasaki, Discovery of 2-hydroxyarbekacin, a new aminoglycoside antibiotic with reduced nephrotoxicity. J Antibiot 2017;1–3.https://doi.org/10.1038/ja.2017.60.
74. D. E. Rogers and M. A. Melly, Further observations on the behavior of staphylococci within human leukocytes. J Exp Med. 1960, 111, 533-558.
75. T. Baba, F. Takeuchi, M. Kuroda, H. Yuzawa, K. Aoki, A. Oguchi, Y. Nagai, N. Iwama, K. Asano, T. Naimi, H. Kuroda, L. Cui, K. Yamamoto, and K. Hiramatsu, Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002, 359, 1819-1827.
76. I. Soni, H. Chakrapani, and S. Chopra. Draft Genome Sequence of Methicillin-Sensitive Staphylococcus aureus ATCC 29213. Genome Announc. 2015, 3, e01095-15.
77. M. Kuroda, T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya,C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu, Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001, 357, 1225- 1240.
78. Performance Standards for Antimicrobial Susceptibility Testing; 30th ed. CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.